TORONTO, Aug. 26, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has granted a total
of 1,140,000 restricted share units (RSUs) to certain directors and
officers of the Company and its subsidiaries under the Company's
Amended and Restated RSU Plan.
Security
|
Number
of shares
|
Grant
Date
|
Vesting
|
RSUs
|
600,000
|
August 26,
2020
|
1/3 vest on grant
date; 1/3 vest on each of the first
and second anniversaries of the grant date
|
RSUs
|
500,000
|
August 26,
2020
|
A quarter on the
achievement of a certain
performance milestone, and
every 6 months thereafter
|
Number of
RSUs
125,000
|
A quarter on the
achievement of a certain
performance milestone, and
every 6 months thereafter
|
125,000
|
A quarter on the
achievement of a certain
performance milestone, and
every 6 months thereafter
A quarter on the
achievement of a certain
performance milestone, and
every 6 months thereafter
|
125,000
125,000
|
Total:
|
500,000
|
RSUs
|
40,000
|
August 26,
2020
|
1/3 vest on each of
the first, second and third
anniversaries of the grant date
|
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both low and high THC medical cannabis products. The
Company has presence in Mexico,
Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at www.khiron.ca, investors.khiron.ca and on
Instagram @khironlife.
Neither the TSX Venture Exchange Inc. ("TSXV") nor its
Regulation Services Provider (as that term is defined in the
policies of the TSXV) accepts responsibility for the adequacy or
accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-restricted-share-unit-grants-301119163.html
SOURCE Khiron Life Sciences Corp.